CSII - CSII STOCK NEWS

Cardiovascular Systems, Inc. (CSII) has completed a minority investment and acquisition option with CarePICS, LLC, a telehealth company focused on peripheral artery disease (PAD) management. The agreement is aimed at enhancing patient outcomes through a virtual care platform enabling multidisciplinary communication. CarePICS addresses the needs of the 18 million Americans affected by PAD, aiming to improve treatment efficiencies and reduce amputations. The specific terms of the investment remain undisclosed.

Cardiovascular Systems, Inc. (NASDAQ: CSII) announced its participation in the 20th Annual Needham Healthcare Conference on April 13, 2021, at 3:00 p.m. ET. The company will host investor meetings and present its innovative interventional treatment systems for peripheral and coronary artery diseases. CSI’s orbital atherectomy system is designed to treat calcified and fibrotic plaque, addressing limitations of existing medical alternatives. Investors can access a webcast of the presentation on CSI's website.

Cardiovascular Systems, Inc. (CSI) has acquired peripheral support catheters from WavePoint Medical, enhancing its portfolio for peripheral vascular intervention (PVI) procedures. These catheters will be branded as the ViperCross™ line and are scheduled for launch in the first half of FY 2022. WavePoint will also develop specialty catheters for treating chronic total occlusions (CTO), expected to be available in FY 2023. This acquisition aims to strengthen CSI’s offerings in both peripheral artery disease and coronary interventions.

Cardiovascular Systems, Inc. (NASDAQ: CSII) has initiated U.S. treatments with the WIRION^® Embolic Protection System, designed for capturing thrombus during vascular interventions. The WIRION showed a major adverse event (MAE) rate of 1.9% in a multicenter study, lower than other devices. Renowned physicians expressed confidence in WIRION's effectiveness and ease of use. CEO Scott R. Ward highlighted its significance in the company's product portfolio aimed at improving patient outcomes. The device received FDA clearance in March 2021.

Cardiovascular Systems, Inc. (NASDAQ: CSII) has announced its participation in four upcoming healthcare conferences, providing management with a platform to meet with investors. Key conference dates include:

• February 25, 2021 - SVB Leerink Global Healthcare Conference at 9:20 a.m. ET
• March 2, 2021 - Raymond James Institutional Investors Conference at 3:00 p.m. ET
• March 9, 2021 - Barclays Global Healthcare Conference at 2:25 p.m. ET
• March 16, 2021 - Oppenheimer Healthcare Conference at 2:30 p.m. ET

Webcasts of these presentations will be accessible on CSI's website, enhancing investor engagement.

Cardiovascular Systems, Inc. (CSII) announced the treatment of its first European patient using the Diamondback 360® Coronary Orbital Atherectomy System (OAS). This system targets calcific coronary artery disease and aims to improve clinical outcomes. Professor Nicolas Van Mieghem highlighted its efficacy, pointing out that it optimizes stent performance in severe cases. The Diamondback 360® received CE Mark in January 2021 and is FDA approved since 2013. CEO Scott Ward expressed excitement for introducing the device in Europe and supporting training for healthcare professionals remotely.

Cardiovascular Systems, Inc. (CSII) reported Q2 fiscal 2021 revenues of $64.2 million, a 6% sequential increase but a 6.1% decrease year-over-year. The company faced challenges due to a spike in COVID-19 cases, impacting procedures in December. Management anticipates Q3 revenues between $60 million and $65 million, indicating a slight sequential decline. Despite these challenges, gross profit margin stood at 78.3% and adjusted EBITDA was $5.2 million. The company is optimistic for 2021 as pandemic effects lessen. Cash and marketable securities totaled $225.1 million.

Cardiovascular Systems, Inc. (CSII) has partnered with Chansu Vascular Technologies, LLC to develop everolimus drug-coated balloons (DCBs) targeting peripheral and coronary artery diseases. This collaboration combines CSI's expertise in treating calcified arterial lesions with Dr. Philippe Marco's experience in drug-coated device development. The DCBs promise sustained anti-restenotic efficacy, with everolimus shown to reduce tissue hyperplasia. As part of the agreement, CSI will provide milestone-based financing and has an option to acquire CVT upon meeting certain development milestones.

Cardiovascular Systems, Inc. (NASDAQ: CSII) has appointed Dr. Sachin H. Jain as an independent board member. With a background as President and CEO of SCAN Group and Health Plan, Dr. Jain brings extensive experience in healthcare delivery and policy. Notably, he has held leadership roles at CareMore, Merck, and the U.S. Department of Health and Human Services. His addition strengthens the board's capacity to tackle healthcare disparities and improve patient outcomes. Following this appointment, CSI's board now includes four independent directors added since July 2019, enhancing governance and strategic direction.